Research Funding

Nebraska EPSCoR FIRST Awards Grant

Deadline for Pre-Proposals:  5 PM, Monday, October 1, 2018

Funded by the National Science Foundation’s (NSF) infrastructure grant to Nebraska EPSCoR, the competitive FIRST Award grant program provides assistance to Nebraska’s early-career, tenure-track faculty. The grants are designed to help early career faculty initiate their research programs and compete more effectively for NSF CAREER grants. Any project that could be supported by a National Science Foundation competitive research grant is eligible.

Approximately six FIRST Award grants are awarded each year; the awards are limited to $25,000 each and require a one-for-one match. An assistant professor in a tenure-leading position in any of the the colleges or universities in the state is eligible to submit a pre-proposal. The faculty member must be in his or her first four years of initial academic appointment at the time of submittal. Any project that potentially could be supported by a NSF competitive research grant is eligible.

Phase one of the application process involves the submission of a short pre-proposal that will be reviewed by a panel comprised of members of Nebraska’s scientific community. Ten or fewer proposals are invited to advance to the final phase: the submission of a full, NSF CAREER-like proposal. Full proposals from these finalists will be evaluated using NSF proposal review criteria by external experts in the field. The Nebraska EPSCoR Committee will select FIRST Award recipients.

Grantees are required to submit a CAREER Award proposal to NSF within the next award period. Check Nebraska EPSCoR’s Requests for Proposals page for submission details and to submit a pre-proposal online.

DoD Breast Cancer Research Funding Opportunities

Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of over diagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

http://cdmrp.army.mil/funding/bcrp

Breakthrough Award Level 1 & 2– Letter of Intent due November 1, 2018

  • Investigators at all academic levels (or equivalent) are eligible to be names as Principal Investigator (PI).
  • Applications from senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged underfunding Level 1 and 2.
  • Each investigator may be named on only one Funding Level 1 application and Funding Level 2 application as a PI or Initiating PI.
  • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
  • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
  • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
  • When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
  • There are no limitations on the number of applications for which an investigator may be named as a
  • Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
  • Additional funds are available for applications submitted under the Partnering PI Option.
  • Clinical trials are not allowed.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Funding Level 1:
  • Maximum funding of $375,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 1 – Partnering PI Option:
  • Maximum funding of $600,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 2:
  • Maximum funding of $750,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Funding Level 2 – Partnering PI Option:
  • Maximum funding of $1M for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

Breakthrough Award Level 3 & 4– Preproposal due September 14, 2018

  • Independent investigators at all academic levels (or equivalent) are eligible to be names as PI.
  • Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
  • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
  • Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
  • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
  • When submitting the pre-application it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
  • Clinical trials are allowed.
  • There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
  • Applications must include two or more breast cancer advocates on their research team.
  • Submission of a pre-proposal is required; application submission is by invitation only.
  • Funding Level 3:
  • Maximum funding of $2.5M in direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
  • Funding Level 3 – Partnering PI Option:
  • Maximum funding of $4M for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
  • Funding Level 4 and Funding Level 4 – Partnering PI Option:
  • Maximum funding of $10M for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

 

DoD Vision Research Program Funding Opportunities

The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Vision Research Program (VRP) to support innovative, high-impact vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 VRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Focused Translational Team Science Award (FTTSA) – Preproposal due September 4, 2018

PIs must be independent investigators at or above the level of Associate Professor (or equivalent) with experience in developing and running large-scale initiatives.

  • Co-investigators may be independent investigators at all academic levels (or equivalent).
  • Preproposal is required; application submission is by invitation only.
  • Support highly collaborative and translational team initiatives that would fundamentally advance the understanding and treatment of vision trauma.
  • Proposed research must focus on eye injury or visual dysfunction as related to a traumatic event.  Examples of trauma include, but are not limited to:
    • Blast, blunt, thermal or chemical trauma;
    • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
    • Ionizing radiation
  • Supports a multifaceted, multidisciplinary and highly coherent investigation with 3-5 teams addressing complementary and synergistic questions that center around a specific trauma.  Examples of questions include, but are not limited to:
    • Elucidation of molecular, cellular, and biophysical mechanisms;
    • Identification of biomarkers and potential therapeutic targets;
    • Development and validation of therapeutic agents and/or devices;
    • Development and validation of drug delivery platforms appropriate for said trauma;
    • Development or improvement of clinically relevant models for said trauma;
    • Design of protection to mitigate the impact of said trauma on eye and vision.
    • The proposal should spell out the goals of individual teams as well as describe the ways for the teams to cooperate and effectively share and utilize the newly acquired knowledge in moving the project forward.
  • Preliminary data required.
  • May include a pilot clinical trial component that collects preliminary data to support the feasibility, rationale and design of subsequent clinical trials.
  • Emphasis is on synergy, translational potential, and strategy to transition findings into products.
  • Maximum funding of $5.0M for direct costs (plus indirect costs)
  • Maximum period of performance is year

 

Investigator Initiated Research Award (IIRA) – Preproposal due September 4, 2018

  • Independent investigators at all academic levels (or equivalent).
  • Preproposal is required; application submission is by invitation only.
  • Supports studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of the military-relevant vision trauma.
  • Must focus on eye injury or visual dysfunction as related to a military-related traumatic event.  Examples of trauma include, but are not limited to:
    • Blast, blunt, thermal or chemical trauma;
    • Trauma caused by directed energy weapons such as laser, microwaves and particle beams;
    • Ionizing radiation
  • Preliminary data required.
  • Clinical trials are not allowed.
  • Maximum funding of $500K for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507